 |
|
|
 |
Correction
Kalden JR. Expanding role of biologic agents in rheumatoid arthritis. J Rheumatol 2002;29 Suppl 66:27-37. Figure 2 was incomplete, and is printed here as intended. We regret the error.
Figure 2. Percentage of patients who achieved an ACR 20% response criteria with combination infliximab/MTX treatment. The dosage and frequency of administration of infliximab varied among groups. All groups received MTX. From Centocor, Inc., with permission.
|
